Healthcare provider profile · identity verified

Endea J Curry, MD

Internal Medicine · MAPLEWOOD, MN · NPI 1073782207

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	405	110
Amlodipine Besylate	Amlodipine Besylate	274	86
Lisinopril	Lisinopril	241	63
Omeprazole	Omeprazole	161	47
Levothyroxine Sodium	Levothyroxine Sodium	158	43
Rosuvastatin Calcium	Rosuvastatin Calcium	143	44
Losartan Potassium	Losartan Potassium	120	35
Metoprolol Succinate	Metoprolol Succinate	103	27
Simvastatin	Simvastatin	100	26
Metformin Hcl	Metformin Hcl	93	23
Hydrochlorothiazide	Hydrochlorothiazide	92	33
Gabapentin	Gabapentin	88	21
Albuterol Sulfate Hfa	Albuterol Sulfate	87	33
Fluticasone Propionate	Fluticasone Propionate	79	31
Metformin Hcl Er	Metformin Hcl	77	25
Furosemide	Furosemide	68	26
Warfarin Sodium	Warfarin Sodium	65	15
Eliquis	Apixaban	60	18
Trazodone Hcl	Trazodone Hcl	52	13
Atenolol	Atenolol	44	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	15
Tamsulosin Hcl	Tamsulosin Hcl	42	11
Carvedilol	Carvedilol	40	14
Metoprolol Tartrate	Metoprolol Tartrate	40	14
Spironolactone	Spironolactone	40	suppressed
Xarelto	Rivaroxaban	40	suppressed
Paroxetine Hcl	Paroxetine Hcl	39	13
Tizanidine Hcl	Tizanidine Hcl	36	14
Pantoprazole Sodium	Pantoprazole Sodium	35	suppressed
Ozempic	Semaglutide	34	suppressed
Sertraline Hcl	Sertraline Hcl	33	12
Fluoxetine Hcl	Fluoxetine Hcl	32	suppressed
Jardiance	Empagliflozin	32	suppressed
Prednisone	Prednisone	32	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	32	suppressed
Glipizide Er	Glipizide	31	12
Clopidogrel	Clopidogrel Bisulfate	30	suppressed
Levetiracetam	Levetiracetam	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	27	suppressed
Famotidine	Famotidine	26	12
Potassium Chloride	Potassium Chloride	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Tramadol Hcl	Tramadol Hcl	20	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Donepezil Hcl	Donepezil Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Nitroglycerin	Nitroglycerin	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Allopurinol	Allopurinol	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	11
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	15	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	14
Mirtazapine	Mirtazapine	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Alendronate Sodium	Alendronate Sodium	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	13	suppressed
Prochlorperazine Maleate	Prochlorperazine Maleate	13	suppressed
Colchicine	Colchicine	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	11	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error